
RayzeBio is a biotechnology company developing transformative radiopharmaceutical therapies for patients living with cancer.
As a wholly-owned subsidiary of Bristol Myers Squibb, RayzeBio is developing transformative radiopharmaceutical therapies for patients living with cancer. This role supports the routine operation of a Quality Control Microbiology laboratory, performing microbiological and environmental monitoring testing in accordance with approved methods and cGMP requirements.
RayzeBio is a biotechnology company developing transformative radiopharmaceutical therapies for patients living with cancer.